InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research note published on Thursday. The firm issued a sell rating on the stock.

Other equities research analysts have also recently issued reports about the company. Piper Sandler reaffirmed an “overweight” rating and set a $4.50 price target on shares of InspireMD in a report on Tuesday, September 17th. Lake Street Capital started coverage on InspireMD in a research note on Wednesday. They set a “buy” rating and a $5.00 price target on the stock.

InspireMD Trading Down 2.5 %

NSPR opened at $3.09 on Thursday. The firm’s fifty day moving average price is $2.66 and its two-hundred day moving average price is $2.68. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.42.

InspireMD (NYSE:NSPR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $1.81 million for the quarter, compared to analysts’ expectations of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same quarter in the previous year, the firm posted ($0.15) earnings per share. On average, sell-side analysts anticipate that InspireMD will post -0.79 EPS for the current fiscal year.

Institutional Trading of InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Parkman Healthcare Partners LLC purchased a new stake in InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned about 0.42% of InspireMD at the end of the most recent reporting period. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.